WORLD NEWS MEDIA DIRECTORY
Explore this media outlet and visit its official website.
Cancer Communications is an open-access, peer-reviewed, English-language oncology journal based in Guangzhou, Guangdong, China, and sponsored by Sun Yat-sen University Cancer Center (SYSUCC). It publishes basic, clinical and translational cancer research for an international readership. The journal is the current title of a publication founded in 1982 as the Chinese Journal of Cancer. It switched from Chinese to English in 2010, took its present name in March 2018, and has been indexed in MEDLINE, Scopus and the Science Citation Index Expanded. Its standard abbreviation is Cancer Commun, and its electronic ISSN is 2523-3548, compared with 1944-446X for its predecessor title.
Cancer Communications is a specialist medical journal, not a general news magazine. Its field is oncology in the full sense: the study of how cancers arise, how they can be prevented and detected, how they are treated, and how the lives of people who survive cancer can be improved. The journal's own renaming editorial in 2018 set out that mission explicitly, saying that it would continue to publish peer-reviewed, open-access, English-language scientific articles in basic, clinical and translational cancer research aiming to improve human health through understanding cancer, preventing cancer onset, reducing cancer mortality and improving the quality of life of cancer survivors worldwide.
Open access is central to the journal's identity. Articles are freely available to readers rather than held behind a subscription paywall, and the journal has long distributed its content through PubMed Central and the Directory of Open Access Journals as well as through its publisher's platform. In its current form, as part of the American Association for the Advancement of Science (AAAS) Science Partner Journals programme, it is described as an open-access, peer-reviewed online journal published in association with Sun Yat-sen University Cancer Center, and articles are published continuously under a Creative Commons Attribution (CC BY) licence.
The journal began in 1982 as the Chinese Journal of Cancer, often abbreviated as CJC. Sun Yat-sen University records state plainly that the CJC was initiated in 1982 and was sponsored by Sun Yat-sen University Cancer Center. For most of its first three decades it was a Chinese-language publication serving China's own oncology community. A 2014 editorial marking its Science Citation Index Expanded coverage noted that, as an official journal of the Chinese Anti-Cancer Association (CACA), CJC had been a leading cancer journal in China and had published monthly since 2000.
Even in its Chinese-language period, the journal was building an international indexing record. The 2014 editorial recorded that CJC had been indexed in MEDLINE from 2002, and was also covered by PubMed Central, the Directory of Open Access Journals, Scopus, the Western Pacific Region Index Medicus and CA databases. That long indexing history matters because the present title did not start from nothing in 2018: it inherited a publication that had been appearing for more than three and a half decades, a monthly rhythm, and a place in the main biomedical databases.
The decisive change in the journal's history came in 2010. In that year the Chinese Journal of Cancer transferred from a Chinese-language journal to an English-language journal. Sun Yat-sen University described the purpose directly: the change was made on the way to making CJC a top oncologic journal with extensive international impact. The 2018 renaming editorial adds that CJC was launched in its 2010 form as the official journal of the Chinese Anti-Cancer Association (CACA) and the US Chinese Anti-Cancer Association (USCACA), and the 2014 editorial likewise noted that in 2010 it also became the official journal of USCACA and was produced with an international editorial board and English-language editors.
The internationalisation drive received institutional support. Sun Yat-sen University reported that CJC gained Type B grant support from the International Impact-promoting Program for Chinese Sci-Tech Journals, with annual national funding of 1,000,000 RMB for three consecutive years. The university also reported early evidence that the English switch was reaching readers abroad: CJC papers were being browsed by readers from 119 countries, with more than 666,000 downloads of all papers and more than 1,900 downloads per paper in 2012, and its papers had been cited in Science Citation Index papers submitted by 282 institutions from 44 countries and regions, including in journals such as Nature Reviews Cancer, Cell and Cancer Cell.
A second milestone followed in 2014. On 22 July 2014, the Chinese Journal of Cancer received notification from Thomson Reuters that its publications starting from 2012 had been accepted for coverage in the Science Citation Index Expanded, available through the Web of Science Core Collection, Biological Abstracts and BIOSIS Previews. An editorial announced the news under the title “The Chinese Journal of Cancer is indexed in Science Citation Index (SCI) Expanded.” Practical consequences followed: because the journal was now tracked for an impact factor, it would receive its first official Journal Citation Reports impact factor in 2015.
The first impact factors showed a rising title. The 2018 renaming editorial recorded that the Journal Citation Report impact factor of CJC increased from 2.814 in 2015 to 4.111 in 2016. Sun Yat-sen University had already noted the journal's climbing domestic recognition before that: on 16 December 2014 CJC was awarded “The Highest International Impact Academic Journal of China” by the Center for International Evaluation Research of Chinese Academic Literatures in Beijing, ranked 23rd among a range of 6,400 Chinese academic journals in the humanities, social sciences and science and technology according to the number of international citations in 2014, up from 55th in 2013.
From March 2018, the journal was published under the new title Cancer Communications. The change was announced by editor-in-chief Rui-Hua Xu in an editorial published on 9 March 2018, “Editorial announcement regarding title change of Chinese Journal of Cancer to Cancer Communications” (Cancer Communications 38, 1; doi: 10.1186/s40880-018-0270-7). Xu stressed continuity as well as change: the journal would be published under the new title with the same scope of publication as the former title, it would continue to be sponsored by Sun Yat-sen University Cancer Center, and it would continue to be indexed in the same services as its predecessor had been since 2014.
Xu framed the new name as a beginning rather than a break, writing that he hoped Cancer Communications would continue to make fundamental contributions to the field of cancer research and help to strengthen communication and collaboration among oncology researchers all over the world. The English, internationally legible title matched the direction set in 2010: a journal rooted in Guangzhou and in a Chinese national cancer centre, but addressed to the worldwide oncology community rather than to a single national readership.
The journal's home institution explains much of its character. Sun Yat-sen University Cancer Center, abbreviated SYSUCC, is a public hospital in Guangzhou affiliated with Sun Yat-sen University. It was founded in March 1964, beginning as the Tumor Hospital in South China, and its founders included Professor Hsieh Chih Kuang, described as a pioneer of clinical radiology and the founding father of radiation oncology in China, and Professor Liang Boqiang, described as the originator of modern pathology in China. A Cancer Institute opened under Liang's leadership a few days after the hospital opened its doors.
Today SYSUCC is a Level III Class A hospital — the highest rank in China — and is described as the largest integrated cancer centre in southern China for care, research, education and prevention, combining medical treatment with training and research. Its stated mission is to cure cancer and bring happiness to people's lives. A journal sponsored by a centre of that scale has a direct supply of clinical and research work behind it, and the centre itself presents Cancer Communications in its own publications, listing the journal's publisher page alongside its official centre website in its annual report. The journal's editorial address, given in the 2018 renaming editorial, is Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
The Science Partner Journals listing summarises the journal's coverage as basic, clinical and translational cancer research, including clinical trials, epidemiology, molecular and cellular biology, and genetics. The AAAS partnership announcement describes the same breadth in other words: the journal disseminates research across the cancer research continuum, spanning basic science, clinical practice and translational studies, and serves as a conduit for findings in molecular biology, genetics, epidemiology and clinical trials, providing a bridge between laboratory discoveries and clinical advancements. It encourages submissions on topics including epidemiology, the molecular mechanisms of tumorigenesis, cellular signalling pathways, genetic mutations, innovative clinical trial designs and translational interventions that bridge bench and bedside.
That three-part scope — basic, clinical and translational — was already the stated scope under the old title. Basic research addresses the mechanisms of cancer at molecular and cellular level; clinical research reports work with patients, including trials of treatments; and translational research connects the two, moving laboratory findings towards diagnosis and therapy and bringing clinical questions back into the laboratory. By holding all three within one title, Cancer Communications presents itself as a comprehensive oncology journal rather than a journal of one technique, one cancer type or one stage of research.
Alongside ordinary research articles, the journal has made a feature of thematic series on timely cancer issues. The 2018 renaming editorial listed series published under its previous title: air pollution and cancer; tumour metastasis; tumour angiogenesis; gastric cancer; and “the 150 most important questions in cancer research and clinical oncology.” That last item was a 2016 paper by Chao-Nan Qian, Wei Zhang and Rui-Hua Xu, “Defeating cancer: the 150 most important questions in cancer research and clinical oncology,” published in the Chinese Journal of Cancer (35(1): 104).
The choice of themes shows the journal working at two levels at once. Series on metastasis and angiogenesis address core processes by which cancers spread and sustain themselves, and are relevant to researchers across many cancer types. A series on air pollution and cancer addresses an environmental exposure question of particular public-health weight, and the gastric cancer series addressed a cancer of major importance in China and East Asia. The “150 most important questions” project took yet another approach, using the journal as a forum to define the agenda of the field itself — what cancer research and clinical oncology most needed to answer — rather than only to report results.
The journal's publishing arrangements have changed as it has internationalised, while its sponsor and editorial home have stayed the same. Its predecessor was published by BioMed Central, the publisher of the 2018 renaming editorial. Sun Yat-sen University Cancer Center later described the journal as produced “with the support of strong scientific research resources from SYSUCC and partnership with the highly-acclaimed publisher, Wiley” — a partnership also reflected in the centre's 2020 annual report, which gave the journal's address as its Wiley Online Library journal page. More recently, AAAS announced a partnership with SYSUCC to publish Cancer Communications as part of its Science Partner Journal programme, with submissions handled through the Editorial Manager system. AAAS states that organisations participating in the programme are editorially independent and responsible for the content published in each journal.
Indexing has remained continuous through these changes. The 2018 editorial confirmed that the journal, like its predecessor since 2014, would be indexed in MEDLINE/PubMed, PubMed Central, the Directory of Open Access Journals (DOAJ), Scopus, the Western Pacific Region Index Medicus, CA and Science Citation Index Expanded (SCIE) continuously. For a medical journal, that combination places its articles in the main routes by which clinicians and researchers actually find literature: PubMed and MEDLINE for biomedical searching, Scopus and the Web of Science for citation tracking, and PubMed Central and DOAJ for open-access discovery.
Under its new name, the journal's measured impact rose sharply. Sun Yat-sen University reported on 29 June 2020 that Clarivate had released the 2019 Journal Citation Reports and that Cancer Communications had been awarded an impact factor of 5.627 — the first time it had surpassed 5.0 — ranking it 49th among 244 oncological journals worldwide and promoting it to the Q1 category. The university described it at that point as being at the forefront of Asian academic oncological journals and the highest-impact-factor journal in the field of oncology in China.
A year later the centre reported a further jump. On 2 July 2021, SYSUCC announced that Cancer Communications had achieved an impact factor of 10.392 for 2020, ranking in Q1 among global oncology journals and making it, in the centre's words, the top comprehensive oncology journal with the highest impact factor in Asia. The same announcements gave a picture of the journal's reach by that stage: it had published more than 1,000 papers from nearly 2,106 institutions in 88 countries and regions, and those papers had been cited over 23,000 times by research institutions in 108 countries and regions. Under the editorial leadership of Professor Rui-Hua Xu — the SYSUCC president and medical oncologist who signed the 2018 renaming editorial — the Guangzhou journal had thus completed the trajectory begun in 2010: from a Chinese-language title founded in 1982, to an English-language, open-access journal read, written for and cited across the international oncology community.
See the official website for current coverage.
Magazines
Buenos Aires, Buenos Aires (CABA), Argentina
English
¡Hola! Argentina ¡Hola! Argentina is the Argentine edition of ¡Hola!, the Spanish celebrity and lifestyle magazine founded in Barcelona in 1944. Launched in Argentina in 2010 with local…
→Magazines
Bayern, Germany
[inne]halten [inne]halten is a Catholic magazine published in Munich for the Archdiocese of Munich and Freising, describing itself as a magazine for society, the good life and spirituality.…
→Magazines
Berlin, Germany
[030] Magazin Since October 1994, [030] Magazin has been one of Berlin's longest-running independent city and scene magazines, documenting the capital's nightlife, music, culture and everyday urban life…
→Use Visit official website. The publisher controls access, subscriptions, schedules and availability.
No. A listing helps identify a source. It is not an endorsement or a guarantee of its reporting.
